Skip to main content

Home/ Dr. Goodyear/ Group items tagged 4.6

Rss Feed Group items tagged

star yu

La Creatinina 4.6 en la Etapa 3 CKD Cómo Tratarlo - 0 views

  •  
    La creatinina 4.6 en la etapa 3 CKD cómo tratarla?Es saber que la creatinina tiene estrecha relación con la enfermedad renal crónica.De acuerdo con el nivel de creatinina, podemos obtener las condiciones renales en general. ¿Por voluntad nivel de creatinina es alta en la enfermedad renal?
star yu

Es Peligroso el Quiste Renal con 4.6 cm - 0 views

  •  
    Un paciente consultó a nuestro médico en línea si es peligroso con 4.6cm. Sí, quiste renal con 4.6 cm ha sido muy peligroso para usted. A continuación le dirá lo que te pasa y qué tipo de tratamiento que debe tomar.
star yu

Cómo Reducir el Nivel de Creatinina desde 4.6 hasta 2.3 para los Pacientes co... - 0 views

  •  
    Un paciente con FSGS quiere bajar su de nivel de creatinina 4.6. ¿Cómo reducir su nivel de creatinina alta? Puede alto nivel de creatinina puede bajar con manera más efectiva? ¿Cómo paciente con FSGS reducir su nivel de creatinina alta? FSGS es un trastorno renal que tiene un vínculo estrecho con el trastorno inmunológico.
Nathan Goodyear

Genetic Determinants of Serum Testosterone Concentrations in Men - 0 views

  • mean serum testosterone concentrations were found to be lower in men with GG than in those with TT genotype for rs12150660
  • men with the CT genotype for rs6258 had lower serum testosterone concentrations than those with CC genotype.
  • The two autosomal SNPs identified by GWAS had a significant influence on the risk of having low serum testosterone (serum testosterone <300 ng/dl) in both the discovery and the replication cohorts with a combined odds ratio (OR) per minor allele of 0.72 (95% CI, 0.65 – 0.79) and 2.7 (95% CI, 2.1 – 3.5) for rs12150660 and rs6258, respectively
  • ...3 more annotations...
  • The risk of having low serum testosterone concentrations increased by the number of risk alleles with an OR of 1.62 (95% CI, 1.41 – 1.86) for each risk allele (Figure S4). Low serum testosterone concentrations were 6.5-times more prevalent in men with ≥3 risk alleles (30.1% prevalence of low serum testosterone) compared to men without any risk allele (4.6% prevalence of low serum testosterone;
  • SNP rs5934505 was associated with serum testosterone without SHBG-adjustment (combined p-value of 1.7×10−9) and with free testosterone (combined p-value of 6.7×10−15), but not with SHBG
  • The mean serum testosterone and calculated free testosterone but not SHBG concentrations were lower in men with T genotype than in those with C genotype for rs5934505
  •  
    Genetic SNP rs5934505 associated with lower total Testosterone and lower calculated free Testosterone.  No effects on SHBG.
Nathan Goodyear

Influence of complications following immediate breast reconstruction on breast cancer r... - 0 views

  •  
    Wound complications and infection increase breast cancer recurrence by 4.6 and 6.15 times respectively.
vishal Parasrampuria

PET a Very Crucial Raw Material For Packaging - 0 views

  •  
    PET has been in use from quite a long time, but recent years showed a great surge in the demand worldwide. Easy availability of the PET material has great emphasis on packaging due to high-quality production with reduced costs. According to a forecast from Smithers Pira, there will be a sustained annual growth of 4.6 percent year-on-year basis in next five years. Other than established economies, transitional and emerging ones become prominent players in the marketplace.
pharmacybiz

Reverse Decision Declining Romosozumab Use For Osteoporosis - 0 views

  •  
    More than 100 NHS clinicians have urged the National Institute for Health and Care Excellence (NICE) to change its decision - declining recommendation of romosozumab, the first new osteoporosis medication for over a decade. In a joint letter published on January 2, the clinicians warned of the consequences of barring access to the drug to those who suffer the bone-weakening disease. The joint letter, led by the Royal Osteoporosis Society (ROS), raised concern over the scarcity of the drug pipeline for osteoporosis and lack of public funding for new research. It quoted recent government research that showed the National Institute for Health Research (NIHR) invested less than £1 million in osteoporosis research in 2020-21, against the £4.6 billion per year cost to the NHS of fractures. Craig Jones, chief executive of the Royal Osteoporosis Society said: "We're calling on NICE and the applicant company to get back round the table and work with us to ensure equal access to this important new treatment.
1 - 7 of 7
Showing 20 items per page